Equities research analysts at StockNews.com assumed coverage on shares of Trevena (NASDAQ:TRVN – Get Free Report) in a research report issued on Sunday. The firm set a “sell” rating on the biopharmaceutical company’s stock.
Trevena Stock Up 2.3 %
TRVN stock opened at $3.98 on Friday. The stock has a market cap of $3.38 million, a price-to-earnings ratio of -1.49 and a beta of 1.03. Trevena has a 52-week low of $3.35 and a 52-week high of $25.75. The business has a fifty day moving average of $3.08 and a two-hundred day moving average of $1.31.
Trevena (NASDAQ:TRVN – Get Free Report) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.01) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.36. The company had revenue of $0.33 million during the quarter. As a group, sell-side analysts anticipate that Trevena will post -32.25 EPS for the current year.
Institutional Inflows and Outflows
Trevena Company Profile
Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.
Featured Stories
- Five stocks we like better than Trevena
- Ride Out The Recession With These Dividend Kings
- CarMax’s Impressive Rally: What Investors Should Watch Next
- ETF Screener: Uses and Step-by-Step Guide
- MarketBeat Week in Review – 9/23 – 9/27
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Wake Up to This Biotech Stock That Still Has Big Potential Upside
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.